|Woburn, Mass. – Aphios Corporation, a clinical-stage biotechnology company developing therapeutic products for cancer and supportive care, HIV/AIDS and Alzheimer's disease, today announced it has been selected as a winner of a 2014 Red Herring Top 100 North America award, which honors 100 outstanding entrepreneurs and promising companies from among approximately 3,000 technology companies each year in the U.S. and Canada.
In the award selection process, Red Herring's editorial staff evaluates companies on both quantitative and qualitative criteria such as financial performance, technological innovation, intellectual property, management quality, business model, customer footprint, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers, and live presentations by 200 finalists at the Red Herring North America event in Monterey, CA on May 14-16.
"In 2014, selecting the top 100 achievers was by no means a small feat," said Alex Vieux, publisher and CEO, Red Herring. "In fact, we had the toughest time in years because so many entrepreneurs had crossed significant milestones so early. But after much thought, rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across North America to the top 100 winners. We believe Aphios Corporation embodies the vision, drive and innovation that define a successful entrepreneurial venture. Aphios should be proud of its accomplishment, as the competition was very strong."
About Aphios Corporation
Aphios Corporation, a clinical-stage biotechnology company, is developing sustainable technologies and products from terrestrial plants, marine organisms and homo sapiens to combat chronic diseases and improve quality of life. Using advanced scientific and engineering principles, we have developed and patented green, enabling technology platforms for improving drug discovery and manufacturing, nanotechnology drug delivery, pathogen inactivation for viral vaccines and virus-free human plasma and biologics and the sustainable manufacturing of biofuels and biochemicals from cellulosic biomass. Based on these platforms, we are developing quality-of-life medicines for health maintenance and disease prevention, and enhanced therapeutics for the treatment of certain cancers and supportive care, infectious diseases, and CNS disorders.